Cargando…

Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda

BACKGROUND: A safe and effective vaginal microbicide could substantially reduce HIV acquisition for women. Consistent gel use is, however, of great importance to ensure continued protection against HIV infection, even with a safe and effective microbicide. We assessed the long-term correlates of con...

Descripción completa

Detalles Bibliográficos
Autores principales: Abaasa, Andrew, Crook, Angela, Gafos, Mitzy, Anywaine, Zacchaeus, Levin, Jonathan, Wandiembe, Symon, Nanoo, Ananta, Nunn, Andrew, McCormack, Sheena, Hayes, Richard, Kamali, Anatoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564905/
https://www.ncbi.nlm.nih.gov/pubmed/23374729
http://dx.doi.org/10.1186/1745-6215-14-33
_version_ 1782258380774047744
author Abaasa, Andrew
Crook, Angela
Gafos, Mitzy
Anywaine, Zacchaeus
Levin, Jonathan
Wandiembe, Symon
Nanoo, Ananta
Nunn, Andrew
McCormack, Sheena
Hayes, Richard
Kamali, Anatoli
author_facet Abaasa, Andrew
Crook, Angela
Gafos, Mitzy
Anywaine, Zacchaeus
Levin, Jonathan
Wandiembe, Symon
Nanoo, Ananta
Nunn, Andrew
McCormack, Sheena
Hayes, Richard
Kamali, Anatoli
author_sort Abaasa, Andrew
collection PubMed
description BACKGROUND: A safe and effective vaginal microbicide could substantially reduce HIV acquisition for women. Consistent gel use is, however, of great importance to ensure continued protection against HIV infection, even with a safe and effective microbicide. We assessed the long-term correlates of consistent gel use in the MDP 301 clinical trial among HIV-negative women in sero-discordant couples in south-west Uganda. METHODS: HIV-negative women living with an HIV-infected partner were enrolled between 2005 and 2008, in a three-arm phase III microbicide trial and randomized to 2% PRO2000, 0.5% PRO2000 or placebo gel arms. Follow-up visits continued up to September 2009. The 2% arm was stopped early due to futility and the 229 women enrolled in this arm were excluded from this analysis. Data were analyzed on 544 women on the 0.5% and placebo arms who completed at least 52 weeks of follow-up, sero-converted or became pregnant before 52 weeks. Consistent gel use was defined as satisfying all of the following three conditions: (i) reported gel use at the last sex act for at least 92% of the 26 scheduled visits or at least 92% of the visits attended if fewer than 26; (ii) at least one used applicator returned for each visit for which gel use was reported at the last sex act; (iii) attended at least 13 visits (unless the woman sero-converted or became pregnant during follow-up). Logistic regression models were fitted to investigate factors associated with consistent gel use. RESULTS: Of the 544 women, 473 (86.9%) were followed for at least 52 weeks, 29 (5.3%) sero-converted and 42 (7.7%) became pregnant before their week 52 visit. Consistent gel use was reported by 67.8%. Women aged 25 to 34 years and those aged 35 years or older were both more than twice as likely to have reported consistently using gel compared to women aged 17 to 24 years. Living in a household with three or more rooms used for sleeping compared to one room was associated with a twofold increase in consistent gel use. CONCLUSION: In rural Uganda younger women and women in houses with less space are likely to require additional support to achieve consistent microbicide gel use. TRIAL REGISTRATION: Protocol Number ISRCTN64716212
format Online
Article
Text
id pubmed-3564905
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35649052013-02-08 Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda Abaasa, Andrew Crook, Angela Gafos, Mitzy Anywaine, Zacchaeus Levin, Jonathan Wandiembe, Symon Nanoo, Ananta Nunn, Andrew McCormack, Sheena Hayes, Richard Kamali, Anatoli Trials Research BACKGROUND: A safe and effective vaginal microbicide could substantially reduce HIV acquisition for women. Consistent gel use is, however, of great importance to ensure continued protection against HIV infection, even with a safe and effective microbicide. We assessed the long-term correlates of consistent gel use in the MDP 301 clinical trial among HIV-negative women in sero-discordant couples in south-west Uganda. METHODS: HIV-negative women living with an HIV-infected partner were enrolled between 2005 and 2008, in a three-arm phase III microbicide trial and randomized to 2% PRO2000, 0.5% PRO2000 or placebo gel arms. Follow-up visits continued up to September 2009. The 2% arm was stopped early due to futility and the 229 women enrolled in this arm were excluded from this analysis. Data were analyzed on 544 women on the 0.5% and placebo arms who completed at least 52 weeks of follow-up, sero-converted or became pregnant before 52 weeks. Consistent gel use was defined as satisfying all of the following three conditions: (i) reported gel use at the last sex act for at least 92% of the 26 scheduled visits or at least 92% of the visits attended if fewer than 26; (ii) at least one used applicator returned for each visit for which gel use was reported at the last sex act; (iii) attended at least 13 visits (unless the woman sero-converted or became pregnant during follow-up). Logistic regression models were fitted to investigate factors associated with consistent gel use. RESULTS: Of the 544 women, 473 (86.9%) were followed for at least 52 weeks, 29 (5.3%) sero-converted and 42 (7.7%) became pregnant before their week 52 visit. Consistent gel use was reported by 67.8%. Women aged 25 to 34 years and those aged 35 years or older were both more than twice as likely to have reported consistently using gel compared to women aged 17 to 24 years. Living in a household with three or more rooms used for sleeping compared to one room was associated with a twofold increase in consistent gel use. CONCLUSION: In rural Uganda younger women and women in houses with less space are likely to require additional support to achieve consistent microbicide gel use. TRIAL REGISTRATION: Protocol Number ISRCTN64716212 BioMed Central 2013-02-01 /pmc/articles/PMC3564905/ /pubmed/23374729 http://dx.doi.org/10.1186/1745-6215-14-33 Text en Copyright ©2013 Abaasa et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Abaasa, Andrew
Crook, Angela
Gafos, Mitzy
Anywaine, Zacchaeus
Levin, Jonathan
Wandiembe, Symon
Nanoo, Ananta
Nunn, Andrew
McCormack, Sheena
Hayes, Richard
Kamali, Anatoli
Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda
title Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda
title_full Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda
title_fullStr Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda
title_full_unstemmed Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda
title_short Long-term consistent use of a vaginal microbicide gel among HIV-1 sero-discordant couples in a phase III clinical trial (MDP 301) in rural south-west Uganda
title_sort long-term consistent use of a vaginal microbicide gel among hiv-1 sero-discordant couples in a phase iii clinical trial (mdp 301) in rural south-west uganda
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564905/
https://www.ncbi.nlm.nih.gov/pubmed/23374729
http://dx.doi.org/10.1186/1745-6215-14-33
work_keys_str_mv AT abaasaandrew longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT crookangela longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT gafosmitzy longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT anywainezacchaeus longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT levinjonathan longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT wandiembesymon longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT nanooananta longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT nunnandrew longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT mccormacksheena longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT hayesrichard longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda
AT kamalianatoli longtermconsistentuseofavaginalmicrobicidegelamonghiv1serodiscordantcouplesinaphaseiiiclinicaltrialmdp301inruralsouthwestuganda